PC
PCSA.US Processa Pharmaceuticals Inc
- Market cap
- USD 4.81M
- P/E
- -
- P/B
- 2.81x
- ROE
- -140.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PCSA.US undervalued?
Graham numberThe Graham number of Processa Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Processa Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Processa Pharmaceuticals Inc yet.
Processa Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 …
Full company profileProcessa Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Processa Pharmaceuticals Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 113K | 5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -12.5K | -1.87K | -630K | -878K | -882K | -875K | -874K | -222.00 | -782.00 | -1.20K | - |
| Operating Income | 2.69M | -1.80M | -4.52M | -3.94M | -15.1M | -12.1M | -20.3M | -11.5M | -12.1M | -14.0M | -14.8M |
| EBITDA | -2.51M | -1.80M | -3.88M | -3.12M | -14.3M | -10.8M | -26.6M | -11.1M | -11.8M | -13.6M | -16.1M |
| Net Income | -3.35M | -1.86M | -3.77M | -3.36M | -19.0M | -11.4M | -27.4M | -11.1M | -11.9M | -13.6M | -253M |
| EPS | -298 | -199 | -353 | -304 | -1,269 | -373 | -851 | -212 | -97 | -10 | -85 |
| Balance Sheet | |||||||||||
| Total Assets | 104K | 2.98M | 13.2M | 10.9M | 25.2M | 26.5M | 8.62M | 5.79M | 3.23M | 7.81M | 182M |
| Total Liabilities | 2.08M | 2.61M | 3.51M | 2.87M | 2.27M | 978K | 1.15M | 797K | 1.53M | 2.24M | 1.86M |
| Shareholders' Equity | -1.98M | 373K | 9.70M | 8.01M | 22.9M | 25.5M | 7.47M | 4.99M | 1.70M | 5.58M | 180M |
| Cash & Short-term Investments | 2.09K | 2.85M | 1.74M | 692K | 15.4M | 16.5M | 6.50M | 4.71M | 1.19M | 5.54M | 180M |
| Total Debt | 1.37M | 2.45M | 230K | 1.03M | 328K | 78.5K | 229K | 151K | 73.5K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -872K | -1.65M | -3.71M | -2.75M | -3.14M | -8.72M | -9.61M | -8.06M | -11.2M | -11.4M | -14.4M |
| Capital Expenditure | 1.40K | 20.6K | 20.5K | 0.00 | 4.00 | 0.00 | 3.00 | 2.78K | 3.24K | 5.00 | 1.33M |
| Free Cash Flow | -873K | -1.68M | -3.73M | -2.75M | -3.14M | -8.72M | -9.61M | -8.07M | -11.2M | -11.4M | -14.4M |
| Ratios | |||||||||||
| ROE | - | -497.5% | -38.8% | -41.9% | -83.0% | -44.8% | -367.1% | -222.9% | -698.6% | -243.2% | -140.5% |
| ROA | -3,215.3% | -62.2% | -28.5% | -30.9% | -75.5% | -43.2% | -318.2% | -192.2% | -367.0% | -173.6% | -139.0% |
| Net Profit Margin | -2,957.2% | -37,126.3% | - | - | - | - | - | - | - | - | - |
| Debt to Equity | - | 6.56x | 0.02x | 0.13x | 0.01x | 0.00x | 0.03x | 0.03x | 0.04x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Processa Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 767K | 51 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:25 on Dec 17, 2025.
Who owns Processa Pharmaceuticals Inc
- Insiders 15.22%
- Institutions 16.34%
- Public & others 68.44%
- Shares outstanding 2.80M
- Free float 2.70M
Top funds holding PCSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 22.8K | 0.82% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 2.09K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 969.00 | 0.03% | 0.00% | Sep 2026 |
Top institutions holding PCSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Connective Capital Management LLC | 85.3K | 3.05% | +20.55% | Jun 2026 |
| Stonepine Capital Management Llc | 55.0K | 1.97% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 22.1K | 0.79% | -11.31% | Jun 2026 |
| Citadel Advisors Llc | 21.3K | 0.76% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 13.3K | 0.48% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 13.3K | 0.47% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 12.7K | 0.46% | 0.00% | Jun 2026 |
| StoneX Group Inc | 11.4K | 0.41% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 10.9K | 0.39% | 0.00% | Jun 2026 |
| UBS Group AG | 7.79K | 0.28% | +207.94% | Jun 2026 |
| Tower Research Capital LLC | 2.50K | 0.09% | +172.22% | Jun 2026 |
| JONES FINANCIAL COMPANIES LLLP | 7.00 | 0.00% | 0.00% | Jun 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citigroup Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
Processa Pharmaceuticals Inc company profile
- Company name
- Processa Pharmaceuticals Inc
- Ticker
- PCSA.US
- Exchange
- USA Stocks
- Listed since
- Oct 10, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- December
- Address
- 601 21st Street, Vero Beach, FL, United States, 32960
- Phone
- 772 453 2899
- Website
- processapharmaceuticals.com
About Processa Pharmaceuticals Inc
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.
Processa Pharmaceuticals Inc management
8- Mr. George K. Ng Esq., J.D.CEO & Director · born 1974
- Mr. Russell L. Skibsted M.B.A.Chief Financial Officer · born 1959
- Dr. Sheila K. Gujrathi M.D.Executive Chair of the Board · born 1970
- Dr. David Young Ph.D., Pharm.D.Co-Founder, President of Research and Development & Director · born 1953
- Mr. Patrick LinCo-Founder, Chief Business & Strategy Officer · born 1965
- Ms. Wendy J. GuyCo-Founder, Chief Administrative Officer & Corporate Secretary · born 1964
- Mr. Gregory J. FlesherChief Operating Officer · born 1970
- Dr. Steven Cha M.D.Senior Vice President of Clinical Research